Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255111 | 1.00 | ADRB3 (0.70) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL7257111 | 1.00 | ADRB3 (0.70) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7251408 | 0.99 | ADRB3 (0.69) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7251411 | 0.99 | ADRB3 (0.69) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL7251839 | 0.94 | ADRB3 (0.72) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7252861 | 0.93 | ADRB3 (0.71) | ADRB3ADRA1AADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL7252857 | 0.93 | ADRB3 (0.71) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL6911204 | 0.92 | ADRB3 (0.70) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL7250660 | 0.92 | ADRB3 (0.75) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL7251200 | 0.92 | ADRB3 (0.77) | ADRB3ADRA1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1238973-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | ADRB3 442/4885ADRA1A 810/4885DRD2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.